Ardelyx, Inc. - Common Stock (ARDX)

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Ardelyx (ARDX) stock surged 15% after Q3 2025 results, beating revenue estimates with strong growth from its drug IBSRELA and raising its full-year guidance.

After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Ardelyx (ARDX) Q2 2025 earnings beat estimates with $97.7M revenue (+33% YoY) and -$0.08 EPS. Strong IBSRELA & XPHOZAH sales drove growth, sparking an 11.6% after-hours stock surge.

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.